
8-K
1
tv505432_8k.htm
FORM 8-K



     







 

 



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October
24, 2018 (October 22, 2018)

 

LONGEVITY
ACQUISITION CORPORATION

(Exact name of registrant as specified in
its charter)

 



    British Virgin Islands
    001-38637
    N/A

    (State or other jurisdiction
of incorporation)
    (Commission
File Number)
    (IRS Employer
Identification No.)

 

Yongda International Tower No. 2277

Longyang Road, Pudong District, Shanghai

People’s Republic of China

(Address of principal executive offices,
including zip code)

 

Registrant’s telephone number, including
area code: (86) 21-60832028

 

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 



    ¨
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     
     

    ¨
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     
     

    ¨
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     
     

    ¨
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging
growth company  x

 

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 








     
     
    

 


Item 5.02.Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.



On October 22, 2018, Feng Peng resigned as a Class I director of Longevity Acquisition Corporation (the “Company”)
to pursue other professional interests.

 

On October 22, 2018, the board of directors (the “Board”)
of the Company appointed Minguang Wang as a Class I director to serve until the 2019 annual meeting of stockholders of the Company.
Mr. Wang has also been appointed to serve as a member of the audit committee of the Board and as the chairman of the compensation
committee of the Board.

 

Minguang Wang has served as a partner of the DeHeng (Ningbo)
Law Offices in China since September 2018. From March 2017 to September 2018, Mr. Wang served as a partner of the Zhejiang Jinzhong
Law Firm in China. From December 2014 to March 2017, Mr. Wang served as a partner of the Beijing Yingke (Ningbo) Law Firm in China
and as managing partner of such firm’s internet finance practice group. From December 2010 to December 2014, Mr. Wang was
the Vice Chairman of Zhejiang Yuhao Law Office in China. From December 2008 to December 2010, Mr. Wang served as a clerk of People's
Court of Yinzhou District in Ningbo City in China. Mr. Wang’s practice focuses on corporate finance transactions, mergers
and acquisitions and internet finance. He has advised more than 20 Chinese companies with respect to their listing on the Chinese
stock exchanges and has advised dozens of internet finance companies and private equity firms in China. Mr. Wang received his LLB
degree from Peking University.

 

There were no arrangements or understandings between Mr. Wang
and any other persons pursuant to which Mr. Wang was appointed as a director of the Company. In addition, there are no family relationships
between Mr. Wang and any director, executive officer, or person nominated or chosen by the Company to become a director or executive
officer. Furthermore, since the inception of the Company, there have been no transactions in which the Company was or is to be
a participant and the amount involved exceeds $120,000, and in which Mr. Wang had or will have a direct or indirect material interest,
and there are currently no such proposed transactions.

 



     
     
    

 

SIGNATURE

  

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.

 





     
    LONGEVITY ACQUISITION CORPORATION
     

     
     
     
     

     Date: October 24, 2018
    By:
    /s/ Matthew Chen 
     

     
     
    Name: Matthew Chen
     

     
     
    Title: Chairman and Chief Executive Officer
     

 








     
    






